Novartis and AstraZeneca Eye Acquisition of Cytokinetics Amid Anticipation of Late-Stage Cardiac Drug Data

　　【Pharmaceutical Network Industry DynamicsRecently, according to media reports and informed sources, Novartis and AstraZeneca, two multinational pharmaceutical companies, may be interested in acquiring biotechnology company Cytokinetics. Cytokinetics is expected to release late-stage data for its heart disease drug this month.
 

Public information shows that Cytokinetics is a clinical-stage biopharmaceutical company primarily dedicated to the discovery and development of novel small-molecule treatments that modulate muscle function to potentially address significant diseases and poor medical conditions. The company is currently in the development stage, focusing on research, developing drug screening technologies, and financing.
 

It is reported that Cytokinetics' core product is omecamtiv mecarbil, an anti-heart failure drug independently developed by Cytokinetics. Amgen holds the global commercialization rights, while Servier possesses the commercialization rights in Europe and the Commonwealth of Independent States (CIS) countries, including Russia.
 

In May 2020, the FDA granted omecamtiv mecarbil Fast Track designation for the treatment of heart failure. In October 2020, the drug was announced to have met its primary endpoint in Phase III clinical trials, but investors seemed disappointed. Some analysts even described it as "mediocre" since it failed to meet secondary endpoints, casting doubt on the developmental prospects of this investigational drug. However, some analysts believed that this therapy does work. At that time, Cytokinetics' stock price fell by nearly 43% due to this news.
 

In addition to omecamtiv mecarbil, Amgen has also collaborated with Cytokinetics on another pipeline, AMG 594. This is an investigational, novel, selective, orally-administered small molecule cardiac troponin activator, primarily indicated for heart failure and other potentially treatable conditions. In preclinical studies, cardiac troponin activation did not alter calcium transients in myocardial cells. In 2020, AMG 594 completed Phase I clinical trials.
 

Data show that heart failure is a clinical syndrome representing the advanced stage of various heart diseases. More than 64 million people worldwide and approximately 10 million in China are affected by heart failure. Heart failure patients have a low chance of survival, posing a serious threat to their quality of life and longevity. Currently, although there are some standard treatments available, the prognosis for patients remains generally poor. Moreover, there is a lack of novel and effective therapies for cardiovascular diseases in clinical practice, leaving many patients with no viable treatment options.
 

It is believed in the industry that there is a significant unmet clinical need in the field of heart failure treatment, and the future market prospects are relatively broad. However, new drug development is characterized by high R&D investment, high risk, and long cycles, making it a formidable task and an enormous challenge for pharmaceutical companies.
 

Currently, insiders said that Cytokinetics is expected to announce the late-stage data of its heart disease drug this month. The news has also attracted widespread attention in the industry.
 

From the news revealed by insiders that both Novartis and AstraZeneca may be interested in acquiring Cytokinetics, it is evident that multinational pharmaceutical companies are also eyeing the field of heart failure treatment. It is reported that in the cardiovascular disease sector, Novartis possesses deep disease knowledge, a comprehensive product portfolio, and a robust future pipeline. AstraZeneca also has ambitious plans in the cardiovascular field; as early as 2013, the company underwent significant strategic restructuring, announcing its focus on three major disease areas: oncology, cardio-metabolic, and inflammation/autoimmunity.
 

It is worth mentioning that as early as October this year, reports indicated that this company, which owns cardiac drugs, was exploring various options after receiving an acquisition offer.
 

Boosted by this news, Cytokinetics' stock price surged on Thursday, closing up about 26%.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.